CRNX vs ZBH
Crinetics Pharmaceuticals, Inc. vs Zimmer Biomet — AI-powered side-by-side comparison
CRNX
Crinetics Pharmaceuticals, Inc.
65
Buy
VS
| Metric | CRNX | ZBH |
|---|
| AI Score |
65
|
69
|
| Price |
$84.35
|
$97.22
|
| P/E Ratio |
-16.70×
|
23.54×
|
| ROE |
-46.9%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
99.2%
|
69.9%
|
| Debt / Equity |
0.00×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
89.2
|
63.1
|
| Beta |
0.1302
|
0.462
|
| Expected Upside |
—
|
+3.7%
|
AI Committee View
Current Innellis committee reasoning for CRNX versus ZBH.
ZBH leads by 4 points.
ZBH scores 69/100 (Buy) versus CRNX at 65/100 (Buy).
CRNX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 2928.4% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 4.5x prices in significant intangible value — Value
- ROE of only -44.2% -- cheap may mean cheap for a reason — Value
- RSI at 89 is in overbought territory — Technical
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical